Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3676)
All Articles published online
|
Feb 14, 2005 (publication date) through Nov 8, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Chen LM, Le HY, Qin RY, Kumar M, Du ZY, Xia RJ, Deng J. Reversal of the phenotype by |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i6/831.htm |
| Number | Citing Articles |
| 1 |
Sharon Eisenberg, Klaudia Giehl, Yoav I. Henis, Marcelo Ehrlich. Differential Interference of Chlorpromazine with the Membrane Interactions of Oncogenic K-Ras and Its Effects on Cell Growth. Journal of Biological Chemistry 2008; 283(40): 27279 doi: 10.1074/jbc.M804589200
|
| 2 |
S Vidic, B Markelc, G Sersa, A Coer, U Kamensek, G Tevz, S Kranjc, M Cemazar. MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo. Cancer Gene Therapy 2010; 17(6): 409 doi: 10.1038/cgt.2009.87
|
| 3 |
Ezharul Hoque Chowdhury. Strategies for tumor-directed delivery of siRNA. Expert Opinion on Drug Delivery 2011; 8(3): 389 doi: 10.1517/17425247.2011.554817
|
| 4 |
Rui Tian, Renyi Qin, Zhiyong Du, Wei Xia, Chengjian Shi. Recombinant adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene suppresses human pancreatic cancer growth. The Chinese-German Journal of Clinical Oncology 2007; 6(5): 464 doi: 10.1007/s10330-007-0013-8
|
| 5 |
Satish Rajasekharan, Thiagarajan Raman. Ras and Ras mutations in cancer. Open Life Sciences 2013; 8(7): 609 doi: 10.2478/s11535-013-0158-5
|
| 6 |
Jin Xu, Chen Jin, Sijie Hao, Guopei Luo, Deliang Fu. Pancreatic cancer: gene therapy approaches and gene delivery systems. Expert Opinion on Biological Therapy 2010; 10(1): 73 doi: 10.1517/14712590903321454
|
| 7 |
Chih-Ping Mao, Chien-Fu Hung, T.-C. Wu. Immunotherapeutic strategies employing RNA interference technology for the control of cancers. Journal of Biomedical Science 2007; 14(1): 15 doi: 10.1007/s11373-006-9131-5
|
| 8 |
Chih-Ping Mao, T.-C. Wu. RNA Interference. Methods in Molecular Biology 2010; 623: 325 doi: 10.1007/978-1-60761-588-0_21
|
| 9 |
Roy Blum, Yoel Kloog. Tailoring Ras-pathway—Inhibitor combinations for cancer therapy. Drug Resistance Updates 2005; 8(6): 369 doi: 10.1016/j.drup.2005.11.002
|
| 10 |
Fang Cheng, Song He. RNA interference: a potent technology in studying and modulating of dendritic cells, and potential in clinical therapy. Molecular Biology Reports 2010; 37(6): 2635 doi: 10.1007/s11033-009-9789-7
|
| 11 |
Sepideh Mirzaei, Mohammad Hossein Gholami, Hui Li Ang, Farid Hashemi, Ali Zarrabi, Amirhossein Zabolian, Kiavash Hushmandi, Masoud Delfi, Haroon Khan, Milad Ashrafizadeh, Gautam Sethi, Alan Prem Kumar. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells 2021; 10(12): 3348 doi: 10.3390/cells10123348
|
| 12 |
Yihui Ma, Yumei Gu, Qiang Zhang, Yongqing Han, Shuangni Yu, Zhaohui Lu, Jie Chen. Targeted Degradation of KRAS by an Engineered Ubiquitin Ligase Suppresses Pancreatic Cancer Cell Growth In Vitro and In Vivo
. Molecular Cancer Therapeutics 2013; 12(3): 286 doi: 10.1158/1535-7163.MCT-12-0650
|
| 13 |
S I Pai, Y-Y Lin, B Macaes, A Meneshian, C-F Hung, T-C Wu. Prospects of RNA interference therapy for cancer. Gene Therapy 2006; 13(6): 464 doi: 10.1038/sj.gt.3302694
|
| 14 |
J Wu, S Liu, J Yu, G Zhou, D Rao, C M Jay, P Kumar, R Sanchez, N Templeton, N Senzer, P Maples, J Nemunaitis, F C Brunicardi. Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform. Cancer Gene Therapy 2014; 21(2): 48 doi: 10.1038/cgt.2013.84
|
| 15 |
Shihe Liu, Nikiforos Ballian, Narasimhaswamy S. Belaguli, Sanjeet Patel, Min Li, Nancy Smyth Templeton, Marie-Claude Gingras, Richard Gibbs, William Fisher, F. Charles Brunicardi. PDX-1 Acts as a Potential Molecular Target for Treatment of Human Pancreatic Cancer. Pancreas 2008; 37(2): 210 doi: 10.1097/MPA.0b013e31816a4a33
|
| 16 |
Dong-Sheng Pei, Jie-Hui Di, Fei-Fei Chen, Jun-Nian Zheng. Oncolytic-adenovirus-expressed RNA interference for cancer therapy. Expert Opinion on Biological Therapy 2010; 10(9): 1331 doi: 10.1517/14712598.2010.512002
|
| 17 |
P Cordelier, C Bienvenu, H Lulka, F Marrache, M Bouisson, A Openheim, D S Strayer, N Vaysse, L Pradayrol, L Buscail. Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth. Cancer Gene Therapy 2007; 14(1): 19 doi: 10.1038/sj.cgt.7700987
|
| 18 |
Chih‐Ping Mao, Yen‐Yu Lin, Chien‐Fu Hung, T‐C. Wu. Immunological research using RNA interference technology. Immunology 2007; 121(3): 295 doi: 10.1111/j.1365-2567.2007.02599.x
|
| 19 |
Ladan Teimoori-Toolabi, Saba Hashemi, Kayhan Azadmanesh, Farnaz Eghbalpour, Farnaz Safavifar, Mohammad Reza Khorramizadeh. Silencing the wild-type and mutant K-ras increases the resistance to 5-flurouracil in HCT-116 as a colorectal cancer cell line. Anti-Cancer Drugs 2015; 26(2): 187 doi: 10.1097/CAD.0000000000000175
|
| 20 |
Natália Meneses Araújo, Ileana Gabriela Sanchez Rubio, Nicholas Pietro Agulha Toneto, Mirian Galliote Morale, Rodrigo Esaki Tamura. The use of adenoviral vectors in gene therapy and vaccine approaches. Genetics and Molecular Biology 2022; 45(3 suppl 1) doi: 10.1590/1678-4685-gmb-2022-0079
|